News Releases

BioSante Pharmaceuticals, Inc. To Present at Future Leaders in the Biotech Industry Conference

LINCOLNSHIRE, Illinois (April 11, 2011) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York City. The conference is sponsored by BioCentury and Thomson Reuters, among others.

Stephen M. Simes, BioSante’s president & CEO, will speak on April 15, 2011 at 10:00 am EDT. He will provide an overview of the company, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program. The webcast will be archived approximately one hour after the live event and will be available for one year.

About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.

Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at:


For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953